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Abstract
Background: There is little available data regarding the epidemiology of herpes zoster (HZ) in Spain. This study's main 
goal was to estimate the annual incidence of HZ in the Autonomous Community of Valencia.
Methods: From December 1st 2006 to December 1st 2007, a prospective study was carried out in 24 primary health 
care centres that together provide care for a population of 36,030 persons aged >14 years. We included all adult 
patients with a clinical diagnosis of HZ who were seen at these centres during the one-year study period. Demographic 
(i.e., age, gender, and area of residence) and clinical data were also collected from these patients.
Results: A total of 146 cases of HZ were identified during the study period. The annual incidence of HZ was 4.1/1,000 
individuals >14 years of age (95% confidence interval [CI]: 3.4-4.7). Cases of HZ were predominantly unilateral and most 
commonly affected women and people living in rural areas. The most frequently reported symptoms were pain, 
dysesthesia and itching. A total of 46% of patients also had underlying illnesses (e.g., chronic diseases and/or 
malignancy) and 24% of patients experienced complications, which were mostly ocular in nature. A total of 91% of 
patients were treated with antiviral drugs. The median time from symptoms onset to diagnosis was 6.3 days (range: 2.0-
8.3).
Conclusions: HZ is a common illness in our region (especially in the older population) that causes a significant clinical 
burden on primary care providers.
Background
Herpes zoster (HZ) is caused by the reactivation of latent
infection with varicella zoster virus (VZV) after primary
varicella infection. The condition is characterised by the
localised eruption of vesicular lesions following the tra-
jectory of a sensory nerve as well as pain and inflamma-
tion of the affected nerve root [1].
The most frequent and debilitating complication of HZ
is postherpetic neuralgia (PHN), which is a form of neu-
ropathic pain that appears in the dermatomes affected by
the VZV infection. The pain associated with PHN is
intense and disabling, and PHN has a significant impact
upon patients' quality of life [2].
The incidence and severity of both HZ and PHN
increase significantly with age [3-7]. The annual inci-
dence of HZ that have been reported in population-based
studies that have been published in several countries
ranges from 1.2 to 4.8 cases per 1000 inhabitants/year.
The lifetime risk of zoster is estimated to be 10-30% and
increases markedly with age, occurring in up to 50% in
people who live to be 85 years of age [3,6-11]. In turn,
PHN affects 10-70% of patients with HZ. This wide range
is partly due to differences in the definitions of PHN that
are used in various studies and to the ages of the study
populations from which these estimates were derived. In
older patients, the prevalence of PHN among patients
with HZ is likely closer to the upper end of that range [2].
An increase in the incidence of HZ has been observed
in some countries through epidemiological surveillance
systems. This increase could be explained by the increase
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in the use of immunosuppressive agents and the develop-
ment and clinical use of biological agents with immuno-
suppressive capacity as well as by other factors that are
still not well known [12,13]. The aging of the population
in the industrialised world [12,13] might have a limited
role in this phenomenon since most of the studies in this
setting present age-adjusted rates. Based on a mathemati-
cal model, it has also been speculated that the prevalence
of HZ may increase in populations that have a high rate of
paediatric vaccination against VZV [5], but thus far, this
theoretical model has not been confirmed by epidemio-
logical data. Moreover, some very recent publications
have concluded that the impact that VZV vaccination
programs have on the incidence of HZ is uncertain
[14,15].
There is little information available concerning the epi-
demiology of HZ in Spain, and studies are needed to eval-
uate the epidemiological and pharmacoeconomical
impact of this disease. The purpose of the present study
was to estimate the incidence as well as the clinical and
epidemiological characteristics of HZ in Spain.
Methods
During a 1-year period (from December 1st, 2006 to
December 1st, 2007), a prospective study was carried out
in 24 primary care GP offices that are part of the public
healthcare system. We randomly selected the offices from
rural, urban, and semiurban areas in the province of
Valencia that we felt were representative of the Autono-
mous Community of Valencia (Spain).
Sample size calculation
Based on an expected incidence of HZ in the adult popu-
lation of 0.4% and a precision of 0.08%, we calculated that
a minimum population of 23,600 people >14 years of age
should be included in the population that was monitored
[6]. The study population assigned to the participating
investigators included 36,030 individuals. This popula-
tion was comprised of 21,500 patients who were 15-49
years of age, 4,893 patients who were 50-59 years of age,
4,057 patients who were 60-69 years of age of age, and
5,580 patients who were ≥ 70 years of age. Additionally,
51% of this population was female. The age and genders
of the patients that were recruited to participate in our
study were similar to those that are observed in general
population (based on data from national registries) [16].
Study population
During the study period, all patients who were >14 years
of age and had a clinical diagnosis of HZ were considered
to be eligible for inclusion. All study participants signed
an informed consent form prior to inclusion in the study.
For each patient who agreed to participate and signed
the consent form, a case report form was completed that
included questions regarding patients' demographic data,
information relating to personal history and previous
clinical disorders that are thought to increase the risk of
HZ and/or its complications, and the clinical characteris-
tics of the HZ episode and its associated complications.
This information was obtained by an interview with the
patient and review of his/her medical history. Patients
with HZ who declined to participate in the study were
anonymously counted as HZ cases to allow a more accu-
rate estimation of the incidence of the disease.
The intensity of the pain that the patients experienced
and the degree to which it interfered with their activities
of daily living were evaluated using a validated and previ-
ously published quantitative scale called the Zoster Brief
Pain Inventory (BPI) [17]. The BPI consists of nine ques-
tions that are divided into two parts: the first part (which
is scored from 0 to 10) assesses the intensity of pain expe-
rienced by the patient during the preceding 24 hours, the
intensity of pain experienced by the patient at the time of
questionnaire administration, the anatomical location of
the referred pain, the use of analgesics to combat the
pain, and the degree to which those analgesics relieved
their pain. The second part of the inventory (which is
likewise scored from 0 to 10) addresses the degree to
which patients' pain interferes with their general activity
level, mood state, mobility, ability to perform their job,
relationships with other people, sleep, and quality of life.
With the purpose of this study we considered as "ocular
complications" all nerve ophthalmic localizations.
The study was approved by the Clinical Research Ethics
Committee of the Dirección General de Salud Pública/
Centro Superior de Investigación en Salud Pública
(CSISP) de la Comunidad Valenciana.
Statistical analysis
The annual incidence of HZ was calculated from the epi-
sodes that were recorded during the study period. The
appearance of new lesions at the same location was con-
sidered to be a relapse of the same episode and was not
counted as a new case. The total number of individuals
assigned to the quota of the participating investigators at
the start of the study was used as the denominator. There
was no substantial variation in the number of individuals
assigned to the participating investigators during the
study period [there was relative increase equal to 0.6%
(216 persons) from study initiation to end of follow-up].
The incidence was calculated globally by gender and by
the predefined age groups (<50 years, 50-59 years, 60-69
years, and ≥ 70 years of age). Comparisons between
groups were performed using Student's t-test for continu-
ous variables with a normal distribution and the Mann-
Whitney U-test for non-normally distributed continuous
variables. The chi-squared test or Fisher's exact test were
u s e d  t o  c o m p a r e  t h e  d i s t r i b u t i o n  o f  d i s c r e t e  v a r i a b l e sCebrián-Cuenca et al. BMC Family Practice 2010, 11:33
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between groups. All p-values < 0.05 were considered to
be statistically significant. All statistical analyses were
performed using the SPSS software package, version 12.0
(SPSS Inc., Chicago, IL, USA).
Results
A total of 146 cases of HZ were recorded during the study
period. Of these 146 patients, 130 (89%) consented to
participate in the study. The patients that we included in
our study were significantly younger than those who
refused to be recruited (61 vs. 73 years, p < 0.01), but the
remaining baseline characteristics were not significantly
different in both groups. Of the patients included in our
study, 64% were women and 38.5% lived in a rural setting.
The mean age of included patients was 61.1 years (SD:
17.7). Additionally, 46% of patients presented with 1 or
more background clinical conditions, which, because of
its physiopathology or suggested treatment, was consid-
ered to predispose patients to the development of HZ or
its complications, specifically PHN. The most frequent
underlying condition with which our patients presented
was chronic disease (30% of the patients), which included
diabetes mellitus, chronic obstructive pulmonary disease,
moderate or severe asthma, rheumatoid arthritis, chronic
liver disease, chronic kidney disease, congenital heart dis-
ease, and systemic lupus erythematosus. The second
most common predisposing condition with which our
patients presented was active malignancy (9%). Prodro-
mic pain was reported by 41% of patients. A total of 33%
of these patients described their pain as severe and 49%
described it as moderate. Table 1 lists the baseline charac-
teristics of the included patients.
The most frequent location of HZ lesions was the tho-
racic region (42.3%) and most patients (96%) had a unilat-
eral presentation of their symptoms. A total of 78% of
patients reported experiencing neuropathic-type pain in
the dermatome in which the skin lesions developed. The
mean pain intensity that the patients experienced, as
assessed by the BPI, was scored as a 3.2 (SD: 2.3). The
mean degree to which the pain interfered with patients'
activities of daily living, which was also assessed by the
BPI, was scored as a 3.2 (SD: 2.7). Dysesthesia was pres-
ent in 87% of patients. Table 2 shows the characteristics
of the initial HZ episode that was experienced by the
study patients. A total of 24% of patients experienced
complications, which most often presented as ocular
problems (mainly conjunctivitis and blepharitis).
In 91.5% of patients, antiviral drugs were prescribed to
treat the HZ episode. The prescription of antiviral drugs
was not associated with the presence of pain at the time
of diagnosis or the time that had elapsed since the
appearance of symptoms (p > 0.05). The median time that
elapsed between the appearance of the viral exanthem to
diagnosis was 4.0 days (IQR: 2.0-8.3).
The estimated global annual incidence of HZ in this
observational cohort study was 4.1 per 1000 individuals
(95% confidence interval [CI]: 3.4-4.7). By age group, the
annual incidence of HZ, was significantly higher in
Table 1: Baseline characteristics of the included patients.
Variable n = 130
Age in years, mean (SD) 61.1 (17.7)
Female gender, n (%) 83 (63.8)
Area of residence
Urban, n (%) 41 (31.5)
Semiurban, n (%) 39 (30)
Rural, n (%) 50 (38.5)
Predisposing clinical conditions† 60 (46.2)
Immunosuppressant use, n (%) 3 (2.3)
Malignancy, n (%) 12 (9.2)
HIV, n (%) 0
Transplant, n (%) 1 (0.8)
Chronic disease*, n (%) 39 (30)
Trauma/burns/radiotherapy, n (%) 3 (2.3)
Other** 6 (4.6)
Not reflected in clinical history, n (%) 2 (1.5)
Complications†, n (%) 31 (23.8)
Ocular, n (%) 11 (8.5)
Bacterial superinfection, n (%) 7 (5.4)
Dysgeusia, n (%) 4 (3.1)
Hypoacusis, vertigo, tinnitus, n (%) 2 (1.5)
Dissemination, n (%) 2 (1.5)
Involvement of other organs, n (%) 1 (0.8)
Other‡, n (%) 12 (9.2)
Use of antiviral agents, n (%) 119 (91.5)
Time elapsed from symptom onset to 
diagnosis, days (SD)
6.3 (5.8)
SD: Standard deviation.
HIV: Human immunodeficiency virus.
We considered the administration of oral or systemic 
corticosteroids or chemotherapy treatment to constitute 
immunosuppressant use.
† Each patient may have more than one baseline clinical 
condition/complication.
* Chronic disease was defined as diabetes mellitus, chronic 
obstructive pulmonary disease, moderate or severe asthma, 
rheumatoid arthritis, chronic liver disease, chronic kidney 
disease, congenital heart disease, and systemic lupus 
erythematosus.
** Other risk factors refer to multisystem atrophy, major 
depression, postsurgical stress, influenza, and polysubstance 
abuse.
‡ Other complications refer to lymphadenopathy, activity 
limitation, fungal infection in the HZ area, allergic reactions to 
treatment, weight loss, anorexia, vomiting, and diarrhoea.Cebrián-Cuenca et al. BMC Family Practice 2010, 11:33
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patients 50-59 years of age (6.7/1,000 inhabitants; 95%:
CI 4.4-9) and in those ≥ 70 years of age (11.1/1,000
inhabitants; 95% CI: 8.3-13.9), compared to those
patients aged from 60 to 69 years (annual incidence of
5.2/1000 inhabitants [95% CI: 3-7.4] and < 50 years (1.3/
1,000 inhabitants [95% CI: 0.9-1.8]). The annual inci-
dence was also higher in females (4.5/1,000 inhabitants;
95% CI: 3.5-5.4) than it was in males (2.7/1,000 inhabit-
ants; 95% CI: 1.9-3.5; p = 0.005). Significant differences
w e r e  a l s o  o b s e r v e d  i n  t h e  i n c i d e n c e  o f  p a i n  b y  a g e
group, which varied from 1/1,000 inhabitants for indi-
viduals <50 years of age to 6.7/1,000 inhabitants for
individuals ≥ 70 years. The percentage of patients expe-
riencing pain at the time of diagnosis, by age group, was
75.9% in the subjects who were <50 years of age, 80% in
the patients who were 50-59 years of age, 90% in the
patients who were 60-69 years of age, and 72.5% in the
patients who were ≥ 70 years of age.
The annual incidence of HZ also differed significantly
(p < 0.001) by place of residence. The annual incidence
was greater in the rural setting (8.8/1,000 for individuals
>14 years of age; 95% CI: 6.4-11.2) than it was in the semi-
urban (3.1/1,000 individuals >14 years of age; 95% CI: 2.2-
4) or urban setting (3.1/1,000 individuals >14 years; 95%
CI: 2.2-3.9).
Discussion
The estimated annual incidence of HZ in our study was
4.1 per 1,000 persons >14 years of age. Other studies that
have been carried out in our country in the primary care
setting have reported similar results. In a study per-
formed in Navarra, which involved a retrospective review
of the computer-based primary care patient records of
patients who were seen between 2005 and 2006 [18], the
mean annual incidence was 4.25 per 1,000 inhabitants (0-
≥ 75 years). In the Autonomous Community of Madrid,
an average annual incidence of HZ was 2.49-3.59 per
1,000 persons (0- ≥ 85 years) was estimated based on
reporting by the local Sentinel Physicians Network
between 1997 and 2004 [19]. Unlike the aforementioned
studies, the present study was specifically designed to
prospectively  estimate the incidence of HZ in real-life
practices.
In a recent retrospective population-based study car-
ried out in the United States in which new cases of HZ
t h a t  w e r e  i d e n t i f i e d  b y  m e d i c a l  r e c o r d s  r e v i e w ,  t h e
observed annual incidence of HZ was 3.6/1,000 adults
>22 years of age [13]. Another study from the US, in
which administrative data were used as the data source,
reported an incidence of 3.2 per 1,000 inhabitants in the
general population (0- ≥ 80 years) [20]. In a recent study
carried out in the United States conducted by Oxman and
Cols [4] in people ≥ 60 years was observed an HZ inci-
dence of 11.12/1,000 persons/year in the control arm of
the clinical trial. By age group, Oxman and Cols reported
a HZ incidence of 10.8/1,000 persons/year among indi-
viduals 60-69 years of age and 11.5/1,000 persons/year
among individuals ≥ 70 years of age in the control arm of
the clinical trial. While the incidence of HZ in the group
≥ 70 is similar to our data (11.1/1,000 inhabitants), the
HZ incidence in the group 60-69 years is higher in
Oxman's study than our study (5.2/1,000 persons). The
reason for this discrepancy is not well understood, but it
could be influenced by the different designs of these stud-
ies (i.e., experimental [4] versus observational [13,20]).
The study by Oxman and Cols' [4] group included more
patients (n = 19,276 patients were included in the control
arm) than the other two studies combined [13,20] (n =
10,821) and moreover, the inclusion/exclusion criteria of
the trial were not very restrictive (exclusion was limited
to immunosuppressed individuals). The differing objec-
tives of the studies (evaluation of the effectiveness of an
intervention [3] vs. an estimation of a population-based
incidence [13,20]) may also have contributed to the dif-
ferences in the findings of these studies.
Results from studies that have been carried out in Euro-
pean countries are also consistent with those obtained in
our study. An incidence of 5.23/1,000 persons/year
among individuals ≥ 50 years of age was reported in a ret-
rospective study that was undertaken in the United King-
Table 2: Characteristics of the initial herpes zoster episode.
n = 130
Location
Ophthalmic, n (%) 13 (10)
Cervical, n (%) 16(12.3)
Thoracic, n (%) 55 (42.3)
Lumbar, n (%) 27 (20.7)
Sacral, n (%) 19 (14.6)
Unilateral, n (%) 125 (96.2)
Bilateral, n (%) 5 (3.8)
Other symptoms
Prodromic pain, n (%) 53 (40.8)
Pain at presentation, n (%) 101 (77.7)
Dysesthesia, n (%) 113 (86.9)
Pruritus, n (%) 101 (77.7)
Malaise, n (%) 70 (53.8)
Headache, n (%) 46 (35.4)
Fever, n (%) 16 (12.3)
Other#, n (%) 7 (5.4)
# Allodynia, diarrhoea, bone pain, irritability, paresthesias, and 
vomiting.Cebrián-Cuenca et al. BMC Family Practice 2010, 11:33
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dom between 2000 and 2006 [21]. An incidence of 4.8/
1,000 persons/year (0->74 years) was observed in a pro-
spective French registry [22] that was specifically
designed to analyse the epidemiology of HZ in that coun-
try.
It should be highlighted that the results of descriptive
epidemiological studies are highly dependent on the
methodology that is used. Accordingly, studies that use
the voluntary reporting of cases and/or review of previ-
ous databases as their sources of information have limita-
tions that are fundamentally related to the coding of
diagnoses, and these limitations can influence the study
findings. Moreover, the results of studies in which
recruitment is carried out in medical outpatient clinics
may be influenced by the characteristics of the healthcare
system of the country in which the study is performed.
For example, prospective studies that have been per-
formed in Holland (3.2 cases/1,000 persons {0->75 years})
[23] and the United Kingdom (0.6-4.3/1,000 persons-year
{ a l l  a g e s } )  [ 2 4 ]  h a v e  r e p o r t e d  l o w e r  i n c i d e n c e s  o f  H Z
compared to our estimated incidence. In the latter study,
the lower incidence that was observed may have been due
to a low rate of inclusion of HZ patients, the exclusion of
patients whose rashes were too old to be confirmed by
laboratory tests (i.e., more than 7 days after onset), and
the inclusion of a cohort of patients whose ethnic diver-
sity was not representative of that of the general popula-
tion. This might have biased the HZ incidence that was
observed because it has been suggested by other studies
that non-Caucasian ethnic groups may have a lower risk
of HZ than Caucasians [6].
The characteristics of our patients and the clinical pre-
sentation of their HZ episodes are consistent with those
that have been reported in other large-scale studies that
have been carried out in developed countries [21-27].
Similar to our study, in studies that have been performed
in Spain [18] and the United States [13,20], over half of
the included patients were >60 years of age, and over two-
thirds were >50 years of age. Moreover, in most studies
[13,18-23,28], the HZ incidence was higher in females
than it was in males. The reasons for these gender-related
differences are not well understood. In our study, the age
distribution was similar among males and females, so an
age bias does not explain the gender-related differences in
HZ incidence that we observed. Some authors have sug-
gested that differences in the utilisation of health care
resources between males and females or different
immune responses to the latent viral infection may offer a
partial explanation for these findings [28]. The observa-
tion of a higher HZ incidence in women is controversial
because an association between repeated exposure to
VZV and a reduction in the risk of developing HZ [5,28]
has been proposed and is currently under debate. Women
typically have more contact with children (including chil-
dren with VZV) than men do [29,30]. Thus, if there is an
association between repeated exposure to VZV and a
reduction in the risk of developing HZ, one would expect
that women would have a lower incidence of HZ than
men [1].
There were not any significant differences between the
age and sex distribution of patients in the rural, semiur-
ban, and urban settings. Therefore, the higher incidence
of HZ that was observed in the rural areas could be par-
t i a l l y  a t t r i b u t a b l e  i n  p a r t  t o  a  h i g h e r  c o n s u l t a t i o n  r a t e
among the rural population due to the lower number of
patients that are assigned to reference GPs in rural prac-
tices.
In our study, we found that people ≥ 70 years of age
reported pain at the time of diagnosis less frequently than
the other age groups. Other authors have described that
with advancing age, the nociceptive pathway undergoes
degenerative changes, which mainly consist of axonal
loss. This age-related nociceptive pathway degeneration
probably explains why elderly patients tend to under-
report pain in many medical conditions, including myo-
cardial infarction, fractures, and arthritis and also proba-
bly plays a key role in the development of neuropathic
pain in patients with HZ [31]. As in other studies [13,22],
we found that the most frequent location of HZ lesions
was the thoracic region (42.3%), followed by the head and
neck (22.3%).
Almost half (46%) of the patients in our study had some
type of underlying illness, but only 11.5% exhibited
immunosuppression related to malignancies or immuno-
suppressive therapy. It can be hypothesised that the pre-
vention of HZ and/or its complications in a population
with a high prevalence of chronic medical conditions
might allow patients to avoid potential interference with
the treatment of their chronic diseases or a worsening of
those chronic diseases. These results, as well as those
published by Oxman [4] (in a cohort of non-immuno-
compromised individuals) support the idea that there is
an important subgroup of patients, particularly the
elderly patients that could be potential candidates for HZ
prevention through vaccination [13].
Non-pain-related complications occurred in 23.8% of
the patients. Although this percentage is higher than the
rates that have been observed in previous studies [13], the
distribution of the complications we observed was similar
to the distribution of symptoms that has been described
in other studies, with ocular complications being the
most frequently reported type of complication. The
higher proportion of complications that were observed in
this study as compared to the study published by Yawn et
al. may be explained, in part, by the different percentages
of immunocompromised patients that were included in
the two studies (12% vs. 8%, respectively) (13).Cebrián-Cuenca et al. BMC Family Practice 2010, 11:33
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The effectiveness of antiviral agents in treating HZ is a
subject of controversy because there is no consensus
regarding their potential capacity to reduce the occur-
rence of severe complications, specifically postherpetic
neuralgia [21,32]. In a recent review to investigate the
effectiveness of antiviral agents in preventing PHN, the
authors concluded that oral acyclovir did not significantly
reduce the incidence of PHN and that there was insuffi-
cient evidence from randomised controlled trials to
determine whether other antiviral treatments prevent
PHN [33]. When such drugs are used, it has been recom-
mended that they should be administered as early as pos-
sible in the course of the illness in order to be effective
[34]. In our study, antivirals were prescribed to 91.5% of
the patients, and the median time that elapsed from the
appearance of the viral exanthem to the initiation of anti-
viral therapy was 4 days (range: 0-29 days).
Conclusions
We conclude that HZ a prevalent disease in Spain and
that its frequency increases with age. Our findings are
consistent with those from other European countries.
The forthcoming introduction of a vaccine to prevent HZ
warrants further large observational studies and pharma-
coeconomical analyses.
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